Table 3 Background and clinicopathological features of AGCLS and non-GCLS with LNM patients

Age (years, mean ± SD)

72 ± 10.7

65 ± 13.7

0.19

Gender

0.57

Male

6 (85.7)

107 (77)

Female

1 (14.3)

32 (23)

Surgical procedures

0.03

TG

6 (85.7)

63 (45.3)

DG

1 (14.3)

70 (50.3)

PG

0 (0)

6 (4.4)

Tumor diameter (mm, mean ± SD)

61.5 ± 31.5

53.1 ± 31.4

0.51

Site of tumor

0.0002

Upper third

6 (85.7)

36 (25.9)

Middle third

1 (14.3)

57 (41.0)

Lower third

0 (0)

46 (33.1)

Number of tumors

0.92

Single

6 (85.7)

130 (93.5)

Multiple

1 (14.3)

9 (6.5)

Macroscopic type

0.19

Superficial

2 (28.6)

33 (23.7)

Borrmann I

0 (0)

5 (3.6)

Borrmann II

2 (28.6)

34 (24.4)

Borrmann III

3 (42.8)

47 (33.8)

Borrmann IV

0 (0)

11 (7.9)

Borrmann V

0 (0)

9 (6.6)

Tumor invasion

0.57

T0

0 (0)

0 (0)

T1

2 (28.6)

25 (18.0)

T2

2 (28.6)

16 (11.5)

T3

0 (0)

47 (33.8)

T4

3 (42.8)

51 (36.7)

Number of harvested LN (mean ± SD)

47.0 ± 27.0

52.2 ± 21.4

0.63

Number of positive LN (mean ± SD)

3.57 ± 2.76

8.28 ± 10.7

0.003

Lymphatic invasion

0.76

ly0

2 (28.6)

8 (5.8)

ly1

1 (14.2)

59 (42.4)

ly2

2 (28.6)

37 (26.6)

ly3

2 (28.6)

35 (25.2)

Vascular invasion

0.8

v0

1 (14.2)

26 (18.7)

v1

3 (42.9)

54 (38.9)

v2

3 (42.9)

42 (30.2)

v3

0 (0)

17 (12.2)

Pathological stage

0.41

I

1 (14.2)

17 (12.2)

II

3 (42.9)

33 (23.8)

III

3 (42.9)

87 (62.6)

IV

0 (0)

2 (1.4)

Survival after surgery

44 ± 16.3

28.2 ± 21.3

0.04

(Months; mean ± SD)

EBV

Positive

7 (100)

-

Negative

0 (0)

-